Moderna Inc (NAS:MRNA)
$ 141.01 8.11 (6.1%) Market Cap: 54.04 Bil Enterprise Value: 43.65 Bil PE Ratio: 0 PB Ratio: 4.21 GF Score: 68/100

Moderna, Inc. - Award from U.S. Government Agency BARDA to Accelerate Development of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus Transcript

Apr 17, 2020 / 12:00PM GMT
Release Date Price: $46.85 (+15.39%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Moderna's conference call. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Ms. Lavina Talukdar. Please go ahead, ma'am.

Lavina Talukdar
Moderna, Inc. - Head of IR

Thank you, operator. Good morning, and welcome to Moderna's conference call. Today, we will discuss the award from the Biomedical Advanced Research and Development Authority, or BARDA, to accelerate the development of mRNA-1273, our vaccine against the novel coronavirus. You can access the press release issued yesterday evening by going to the Investors section of our website.

Today on this call, we have Stéphane Bancel, Chief Executive Officer; Stephen Hoge, President; Tal Zaks, Chief Medical Officer; Juan Andres, Chief Technical Operations and Quality Officer; and Lorence Kim, Chief Financial Officer.

Before we begin, please note that this conference call will include forward-looking statements. Please see our SEC filings for important risk factors that could

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot